Protective effect by cell-free antigen obtained from culture supernatant of phase I Bordetella bronchiseptica.
The cell-free antigen (CFA), with highly hemagglutination activity, obtained from the culture supernatant of Bordetella bronchiseptica was compounded with oil adjuvant to make a component vaccine (CFAV). In the immunization trial in mice, the offsprings whose mothers were immunized with CFAV escaped from death when challenged intrapleurally with virulent strain of B. bronchiseptica. The protective indices (difference of LD50 dose of the challenge strain between immunized and control groups) of the offsprings from CFAV-immunized mothers were over 3.0 in common logarithm value. Moreover, about 90% of the offsprings from CFAV-immunized mothers were negative in nasal turbinate atrophy, while over 80% of them from non-immunized mothers showed obvious turbinate atrophy when challenged intranasally with virulent strain. On the one hand, remarkable differences in the number of bacteria recovered from nostrils were observed between both test groups. It was concluded that CFAV is a very effective vaccine against B. bronchiseptica infection in animals.
Ohgitani
T
T
Division of Veterinary Microbiology, Kyoto Biken Laboratories, Japan.
Uchida
C
C
Okabe
T
T
Sasaki
N
N
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology*; D001428:Bacterial Vaccines; D001885:Bordetella Infections / Q000517:prevention & control / Q000662:veterinary*; D016950:Bordetella bronchiseptica / Q000276:immunology*; D001982:Bronchial Diseases / Q000517:prevention & control / Q000662:veterinary; D006385:Hemagglutination Inhibition Tests; D007928:Lethal Dose 50; D051379:Mice; D012222:Rhinitis, Atrophic / Q000517:prevention & control / Q000662:veterinary; D013047:Specific Pathogen-Free Organisms
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines